3,611 Shares in Quest Diagnostics Incorporated $DGX Purchased by Vise Technologies Inc.

Vise Technologies Inc. bought a new position in Quest Diagnostics Incorporated (NYSE:DGX) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 3,611 shares of the medical research company’s stock, valued at approximately $765,000.

A number of other large investors have also made changes to their positions in the company. Key Financial Inc grew its position in Quest Diagnostics by 1,728.6% during the 1st quarter. Key Financial Inc now owns 128 shares of the medical research company’s stock worth $25,000 after purchasing an additional 121 shares in the last quarter. Quattro Advisors LLC purchased a new stake in shares of Quest Diagnostics in the fourth quarter valued at $25,000. DV Equities LLC acquired a new stake in shares of Quest Diagnostics in the fourth quarter worth $27,000. Sittner & Nelson LLC acquired a new stake in shares of Quest Diagnostics in the fourth quarter worth $29,000. Finally, McIlrath & Eck LLC purchased a new position in shares of Quest Diagnostics during the fourth quarter valued at $32,000. Institutional investors and hedge funds own 88.06% of the company’s stock.

Insider Activity at Quest Diagnostics

In other Quest Diagnostics news, SVP Mark E. Delaney sold 1,600 shares of Quest Diagnostics stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $235.18, for a total value of $376,288.00. Following the transaction, the senior vice president directly owned 10,335 shares of the company’s stock, valued at $2,430,585.30. The trade was a 13.41% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $194.14, for a total value of $1,941,400.00. Following the transaction, the chief executive officer owned 132,423 shares of the company’s stock, valued at approximately $25,708,601.22. This trade represents a 7.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 19,747 shares of company stock worth $3,947,088 in the last 90 days. 0.88% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on DGX shares. Wall Street Zen upgraded Quest Diagnostics from a “hold” rating to a “buy” rating in a report on Tuesday, July 28th. Mizuho raised their price target on shares of Quest Diagnostics from $235.00 to $260.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. UBS Group boosted their price objective on shares of Quest Diagnostics from $220.00 to $232.00 and gave the company a “neutral” rating in a research report on Friday, July 24th. JPMorgan Chase & Co. upped their price objective on shares of Quest Diagnostics from $220.00 to $250.00 and gave the company a “neutral” rating in a research note on Tuesday, July 28th. Finally, Robert W. Baird increased their target price on shares of Quest Diagnostics from $236.00 to $255.00 and gave the stock a “neutral” rating in a research report on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat, Quest Diagnostics has a consensus rating of “Moderate Buy” and an average price target of $235.31.

Quest Diagnostics Stock Performance

NYSE:DGX opened at $244.34 on Monday. Quest Diagnostics Incorporated has a 1 year low of $171.18 and a 1 year high of $245.68. The firm’s fifty day simple moving average is $219.35 and its 200 day simple moving average is $205.29. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.72. The firm has a market capitalization of $26.97 billion, a PE ratio of 25.94, a PEG ratio of 2.25 and a beta of 0.56.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Thursday, July 23rd. The medical research company reported $3.12 EPS for the quarter, topping the consensus estimate of $2.82 by $0.30. The firm had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $2.97 billion. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The business’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.62 EPS. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. On average, sell-side analysts anticipate that Quest Diagnostics Incorporated will post 11.15 EPS for the current year.

Quest Diagnostics Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 21st. Investors of record on Tuesday, October 6th will be given a dividend of $0.86 per share. This represents a $3.44 annualized dividend and a dividend yield of 1.4%. The ex-dividend date of this dividend is Tuesday, October 6th. Quest Diagnostics’s payout ratio is currently 36.52%.

Quest Diagnostics Company Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.